CAG-Cre AAV (Serotype 1)

CAG-Cre AAV (serotype 1) is an advanced tool in the field of genetic engineering and therapeutic research. This engineered viral vector, AAV serotype 2/1, ingeniously combines the capsid of AAV1 with the inverted terminal repeats (ITRs) of AAV2. This combination is specifically designed to take advantage of the high transduction efficiency associated with AAV1, especially in muscle cells, and the reliable and efficient replication and packaging properties provided by the ITRs of AAV2.

Central to the function of CAG-Cre AAV is the binding of Cre recombinase, a key protein in the Cre-lox recombination system. This enzyme promotes precise site-specific recombination events, allowing for targeted modification of genomic sequences. When delivered to cells, Cre recombinase can excise specific DNA segments flanking the loxP sites, allowing for controlled activation, inactivation, or exchange of genes. The basis for the expression of Cre recombinase in CAG-Cre AAV is the CAG promoter, which consists of a fusion of the cytomegalovirus (CMV) early enhancer element and the chicken β-actin promoter. CAG-Cre AAV (serotype 1) is not only a key research tool for manipulating gene expression in vitro , but also serves as a control in therapeutic and experimental settings.